0001395064-20-000056.txt : 20200515 0001395064-20-000056.hdr.sgml : 20200515 20200515060344 ACCESSION NUMBER: 0001395064-20-000056 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200515 FILED AS OF DATE: 20200515 DATE AS OF CHANGE: 20200515 FILER: COMPANY DATA: COMPANY CONFORMED NAME: TAKEDA PHARMACEUTICAL CO LTD CENTRAL INDEX KEY: 0001395064 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38757 FILM NUMBER: 20880410 BUSINESS ADDRESS: STREET 1: 1-1, NIHONBASHI-HONCHO 2-CHOME, CHUO-KU CITY: TOKYO STATE: M0 ZIP: 103-8668 BUSINESS PHONE: 81332782111 MAIL ADDRESS: STREET 1: 1-1, NIHONBASHI-HONCHO 2-CHOME, CHUO-KU CITY: TOKYO STATE: M0 ZIP: 103-8668 6-K 1 form6k-1x051520.htm FORM 6-K Document



FORM 6-K


U.S. SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549


Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
For the month of May 2020

 Commission File Number: 001-38757
TAKEDA PHARMACEUTICAL COMPANY LIMITED
(Translation of registrant’s name into English)

1-1, Nihonbashi-Honcho 2-Chome
Chuo-ku, Tokyo 103-8668
Japan
(Address of principal executive offices)


Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F  ☒            Form 40-F  ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ☐





Information furnished on this form:
EXHIBIT



SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
TAKEDA PHARMACEUTICAL COMPANY LIMITED
Date: May 15, 2020By:/s/ Takashi Okubo
Takashi Okubo
Global Head of Investor Relations



        





News Release



Takeda Announces Candidates for New Directors

Osaka, Japan, May 15, 2020, --- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it has decided the candidates for new Directors which will be proposed to the 144th Ordinary General Meeting of Shareholders in June 2020. The candidates are as follows;

1.Candidates for Non-Audit and Supervisory Committee Directors
NameCategoryCurrent Role
Christophe WeberInternalExisting
Representative Director,
President & Chief Executive Officer
Masato IwasakiInternalExistingDirector, President, Japan Pharma Business Unit
Andrew PlumpInternalExistingDirector, President, Research & Development
Constantine Saroukos
InternalExistingDirector, Chief Financial Officer
Masahiro SakaneExternalExistingExternal Director, Chair of the Board Meeting
Olivier BohuonExternalExistingExternal Director
Jean-Luc ButelExternalExisting
External Director
Ian ClarkExternalExistingExternal Director
Yoshiaki FujimoriExternalExistingExternal Director
Steven GillisExternalExistingExternal Director
Shiro KuniyaExternalExistingExternal Director
Toshiyuki ShigaExternalExistingExternal Director






2.Candidates for Audit and Supervisory Committee Directors
NameCategoryCurrent Role
Yasuhiko Yamanaka
Internal
Existing
Director, Full-time Audit & Supervisory Committee member
Koji Hatsukawa
External
ExistingExternal Director, Chairperson of Audit & Supervisory Committee
Emiko HigashiExternalExistingExternal Director, Audit & Supervisory Committee member
Michel OrsingerExternalExistingExternal Director, Audit & Supervisory Committee member

Media Contact:
Kazumi Kobayashi
kazumi.kobayashi@takeda.com
+81 (0) 3-3278-2095


###